Year: 2020
Language: English
Author(s): World Federation of Hemophilia
In this session from the WFH 2020 Virtual Summit, Mayss Naccache, Emily Ayoub, Toong Youttananukorn and Ellia Tootoonchian discuss:
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.
Publishing in Haemophilia—the official journal of the WFH—presents both opportunities and challenges for researchers and practitioners in the field. While
The World Bleeding Disorders Registry (WBDR) 2023 Data Report provides aggregate data on more than 14,000 people with hemophilia &
The Report on Annual Global Survey (AGS) includes demographic and treatment data, providing a global snapshot of people with hemophilia,
The World Bleeding Disorders Registry (WBDR) 2022 Data Report provides aggregate data on more than 11,000 people with hemophilia around
The presentations and discussions of the second edition of the WFH Global Policy and Access Summit (GPAS) center around improving
The Report on Annual Global Survey (AGS) includes demographic and treatment data, providing a global snapshot of people with hemophilia,
